Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Elispot

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    157 result(s) found for: Elispot. Displaying page 1 of 8.
    1  2  3  4  5  6  7  8  Next»
    EudraCT Number: 2019-002233-11 Sponsor Protocol Number: ELISPOT-TC Start Date*: 2020-01-16
    Sponsor Name:Dr. José González Costello.Unidad de Insuficiencia cardíaca avanzada y Trasplante cardíaco. Hospital Univ. Bellvitge
    Full Title: The proposed study is a phase IV, randomized, controlled, multicenter and open clinical trial, with two parallel groups, to evaluate the effectiveness of a preventive strategy against CMV infection...
    Medical condition: We will investigate the benefits of monitoring the CMV-specific cellular response using the ELISPOT INF-y technique in patients with a positive serology against CMV, allowing the individualization ...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10058666 Cytomegalovirus infection reactivation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-000732-28 Sponsor Protocol Number: M14P5E1 Start Date*: 2006-04-03
    Sponsor Name:Chiron S.r.l.
    Full Title: A Phase IV, Single Centre, Open-label Study to Investigate the Kinetics of the B Cell Response to the C saccharide component of Chiron’s Meningococcal C Conjugate Vaccine (Menjugate®) Administered ...
    Medical condition: Healthy subjects without known medical conditions will be vaccinated against Neisseria meningitidis serogroup C. Active prevention of meningococcal C disease caused by Neisseria meningitidis serogr...
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-004445-17 Sponsor Protocol Number: hCMV2013 Start Date*: 2014-03-05
    Sponsor Name:HOSPITAL UNIVERSITARI DE BELLVITGE
    Full Title: A PROSPECTIVE RANDOMIZED STUDY FOR PREDICTING HUMAN CYTOMEGALOVIRUS (hCMV) INFECTION ACCORDING TO BASELINE hCMV-SPECIFIC T-CELL RESPONSE IN KIDNEY TRANSPLANT PATIENTS
    Medical condition: cytomegalovirus infection in renal tranplant recipients
    Disease: Version SOC Term Classification Code Term Level
    16.1 10021881 - Infections and infestations 10011831 Cytomegalovirus infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-002378-68 Sponsor Protocol Number: SIRES Start Date*: 2007-10-30
    Sponsor Name:SERVICIO NEFROLOGIA HOSPITAL BELLVITGE
    Full Title: Estudio piloto de Selección de la Inmunosupresión basado en un régimen basado en inhibidores de CNI o libre de CNI dependiendo de la aloreactividad donante-especifica mediante el ensayo ELISPOT en ...
    Medical condition: PATIENTS THAT RECEIVE A FIRST RENAL ALLOGRAFT TRANSPLANTATION. It has been shown that the assessment of the donor specific T-cell alloimmune response can be successfully performed by using new too...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10023438 Kidney transplant LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-004962-33 Sponsor Protocol Number: M14P5 Start Date*: 2005-03-09
    Sponsor Name:Chiron S.r.l.
    Full Title: A Phase IV, Single Centre, Open-label Study to Investigate the Kinetics of the B Cell Response to the First and the Third Immunization with Chiron Meningococcal C Conjugate Vaccine Menjugate® Admin...
    Medical condition: Healthy subjects without known medicial conditions will be vaccinated against Neisseria meningitidis serogroup C. Active prevention of meningococcal C disease caused by Neisseria meningitidis serog...
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-001954-88 Sponsor Protocol Number: IdIx Start Date*: 2015-12-03
    Sponsor Name:Helsinki University Centrel Hospital
    Full Title: Immune response to intradermally administrated Ixiaro in healthy adults: a randomized study
    Medical condition: 18-64 years old volunteers with general good health
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-005047-32 Sponsor Protocol Number: H-100-002 Start Date*: 2018-09-27
    Sponsor Name:Hookipa Biotech GmbH
    Full Title: A Randomized, Placebo-Controlled, Phase 2 Study of HB-101, a Bivalent Cytomegalovirus (CMV) Vaccine, in CMV-Seronegative Recipient (R-) Patients Awaiting Kidney Transplantation from Living CMV-Sero...
    Medical condition: Prevention of clinically significant cytomegalovirus (CMV) infection
    Disease: Version SOC Term Classification Code Term Level
    21.1 10042613 - Surgical and medical procedures 10072247 Cytomegalovirus immunisation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) BE (Completed) FR (Completed) AT (Completed) NO (Completed) DE (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2010-022693-14 Sponsor Protocol Number: METc2010.214 Start Date*: 2010-09-24
    Sponsor Name:university medical centre groningen
    Full Title: A study of humoral and cellular-mediated immune response in Monoclonal gammopathy of Undetermined Significance after vaccination with trivalent inactivated influenza vaccine (influvac)
    Medical condition: Monoclonal Gammopathy of Undetermined significance
    Disease: Version SOC Term Classification Code Term Level
    12.1 10027522 MGUS LLT
    12.1 10022005 Influenza viral infections HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-002293-39 Sponsor Protocol Number: BIOIMMUN Start Date*: 2017-10-10
    Sponsor Name:ORIOL BESTARD
    Full Title: MULTICENTER, RANDOMIZED STUDY, TO EVALUATE THE EFFECTIVENESS OF INDIVIDUALIZATION OF IMMUNOLOGICAL RISK BASED ON SELECTIVE BIOMARKERS (DISPARITY OF HLA EPLETS AND ELISPOT-γ) TO OPTIMIZE IMMUNOSUPPR...
    Medical condition: PROPHYLAXIS OF REJECTION AFTER KIDNEY TRANSPLANTATION
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10023439 Kidney transplant rejection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2022-003456-13 Sponsor Protocol Number: DEN-313 Start Date*: 2022-12-21
    Sponsor Name:Takeda Vaccines, Inc.
    Full Title: An Open Label, Phase 2 Study to Investigate Cell-mediated Immunity and Safety of a Tetravalent Dengue Vaccine Candidate (TDV) Administered Subcutaneously in Healthy Children Aged 4 to 16 Years
    Medical condition: Dengue fever
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10012312 Dengue fever virus infection LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2007-005645-38 Sponsor Protocol Number: TBEB08 Start Date*: 2008-01-17
    Sponsor Name:Clinical Institute of Virology, Medical University of Vienna
    Full Title: B-cell memory and humoral immune response after primary immunization against tick borne encephalitis (TBE) in the elderly
    Medical condition: This study will investigate immunity against tick-borne encephalitis (TBE) following primary TBE vaccination in healthy volunteers 18-30 years or > 60 years who fulfill the local criteria for TBE v...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10036897 Prophylactic vaccination LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2021-001391-42 Sponsor Protocol Number: Speed-Covid Start Date*: 2021-05-12
    Sponsor Name:Medical University of Graz
    Full Title: Characterisation of the effects of Spermidine on the immune response to Covid-19 vaccine in older people - a feasibility study
    Medical condition: For assessing the immune cell function after COVID-19 vaccine, peripheral blood mononuclear cells (PBMC) will be separated after blood sampling and measurements as follows will be done: • FACS anal...
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-002356-37 Sponsor Protocol Number: VAX-TRES Start Date*: 2021-09-22
    Sponsor Name:Fundació Clinic per a la Recerca Biomèdica (FCRB)
    Full Title: Study about the response to the administration of a third dose of mRNA-1273 vaccine (COVID19 vaccine Moderna) in renal transplants with immunological failure initial to vaccination
    Medical condition: COVID19 vaccine in kidney transplant patients
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004865 10084464 COVID-19 immunization LLT
    23.1 100000004865 10084465 COVID-19 vaccination LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-002358-31 Sponsor Protocol Number: LTR138 Start Date*: 2006-09-11
    Sponsor Name:RIVM
    Full Title: Specific B-cell Memory After a Single Dose or Booster MenC Conjugate Vaccination: a Pilot Study in Adults
    Medical condition: Bacterial meningitis is caused by several pathogens such as Hib, Streptococcus pneumoniae and MenC. A MenC conjugate vaccination was introduced into the National Vaccination Program at the age of 1...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2005-003071-20 Sponsor Protocol Number: C060401 Start Date*: 2005-09-20
    Sponsor Name:FIT Biotech Oyj Plc
    Full Title: Immunogenicity and therapeutic effects of GTU-MultiHIV B clade DNA vaccine. A randomized, controlled, phase II clinical trial in treatment-naive HIV-positive subjects
    Medical condition: Treatment naive HIV infected individuals
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-016773-15 Sponsor Protocol Number: HepVac Start Date*: 2010-01-13
    Sponsor Name:Matti Ristola
    Full Title: A Randomized, Controlled, Open-label Study of Comparing Immunogenicity of Sequential Hepatitis B and Hepatitis A Vaccination vs Vaccination with a Dual Hepatitis B and Hepatitis A Vaccine among HI...
    Medical condition: Immunisaatio A- ja B-hepatiittia vastaan HIV-infektoituneilla henkilöillä
    Disease: Version SOC Term Classification Code Term Level
    12.0 10021430 Immunisation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-001595-22 Sponsor Protocol Number: P/2012/159 Start Date*: 2015-10-19
    Sponsor Name:CHRU de Besançon
    Full Title: Projet EVER IMMUN Breast Cancer 2012: Etude de la réponse immunitaire T CD4 anti-tumorale chez des patientes traitées pour un cancer du sein métastatique par évérolimus dans le cadre de l’AMM
    Medical condition: cancer du sein métastatique
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-000836-24 Sponsor Protocol Number: IIV-406 Start Date*: 2019-06-19
    Sponsor Name:National Institute of Health and the Environment
    Full Title: Immune responses to influenza and pneumococcal conjugate vaccines in older adults compared to middle-aged adults and adults.
    Medical condition: Healthy volunteers above 25 years of age
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-020150-34 Sponsor Protocol Number: V212-001-01 Start Date*: 2010-10-28
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Clinical Trial to Study the Safety, Tolerability, Efficacy, and Immunogenicity of V212 in Recipients of Autologous Hematopoiet...
    Medical condition: Incidence of Herpes Zoster in recipients of Autologous HCTs
    Disease: Version SOC Term Classification Code Term Level
    17.1 10021881 - Infections and infestations 10019974 Herpes zoster PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed) ES (Completed) SE (Completed) CZ (Completed) GB (Completed) LT (Completed) IT (Completed) BE (Completed) PT (Completed)
    Trial results: View results
    EudraCT Number: 2010-023156-89 Sponsor Protocol Number: V212-011 Start Date*: 2011-02-24
    Sponsor Name:Merck Sharp & Dohme Corp. a subsidiary of Merck & Co., Inc
    Full Title: Ensayo clínico en fase III, aleatorizado y controlado con placebo para estudiar la seguridad y la eficacia de V212 en pacientes adultos con tumor sólido o neoplasia hematológica. A Phase III Rando...
    Medical condition: Incidence of Herpes Zoster in adults with solid tumor or hematologic malignancy Incidencia de Herpes Zoster en pacientes adultos con tumor sólido o neoplasia hematológica.
    Disease: Version SOC Term Classification Code Term Level
    13 10019974 Herpes zoster LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) CZ (Completed) GB (Completed) SK (Completed) AT (Completed) BE (Completed) EE (Completed) LT (Completed) GR (Completed) BG (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 13 08:29:08 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA